Pilot study of abbreviated chemotherapy based on early positron emission tomography in Hodgkin lymphoma

Study Status

Open to Enrollment

Study Description

The purpose of this study is to determine the progression-free survival at 36 months for patients with Hodgkin lymphoma who achieve a response, as demonstrated by a negative PET scan, after one cycle of ABVD chemotherapy. 

Patients will be treated with ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) on Days 1 and 15 of each cycle according to standard treatment guidelines.

Patients whose PET scans are negative after one cycle of treatment will receive two more cycles (for a total of three cycles) of chemotherapy. Treatment cycles will be repeated every 28 days. Patients continuing on study will be evaluated for response after Cycle 1 and after completion of treatment.

Patients whose PET scans are positive after one cycle of treatment will go off study and continue therapy as per their primary treating physician.

Disease Status and/or Stage

Untreated Hodgkin Lymphoma


Weill Cornell Medical College

Key Eligibility

  • Men and women age 18 and older
  • Documented classical Hodgkin lymphoma
  • No prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma
  • Must have at least one hypermetabolic lesion identifiable on initial PET scan
  • More detailed eligibility discussed when you contact the study team

Principal Investigator

Rebecca Elstrom, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page